Premium
Lignocaine disposition in blood in epilepsy.
Author(s) -
Routledge PA,
Stargel WW,
Finn AL,
Barchowsky A,
Shand DG
Publication year - 1981
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1981.tb01286.x
Subject(s) - anticonvulsant , epilepsy , pharmacokinetics , plasma concentration , disposition , pharmacology , anesthesia , blood plasma , free fraction , medicine , drug , chemistry , endocrinology , psychology , social psychology , psychiatry
1 The plasma concentration of alpha 1‐acid glycoprotein (AAG) was significantly greater in 27 epileptic subjects receiving anticonvulsants compared with 27 age‐ and sex‐matched drug‐free control subjects. 2 Increased AAG concentration was associated with enhanced lignocaine binding in the plasma of epileptics. 3 Increased AAG concentration was also associated with a redistribution of lignocaine out of red cells and into plasma thus lowering the blood to plasma concentration ratio. 4 Enhanced lignocaine binding in epileptics receiving anticonvulsant therapy may result in lower free (unbound) plasma concentrations of the drug compared to normal subjects with equivalent total plasma lignocaine concentrations.